Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
TVI-Brain-1
i
Other names:
TVI-Brain-1
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
TVAX Biomedical
Drug class:
Immunostimulant
Related drugs:
‹
RG6180 (4)
AV-GBM-1 (3)
SV-BR-1-GM (2)
tirvalimogene teraplasmid (2)
OSE 2101 (2)
lifileucel (1)
BNT111 (1)
EVX-01 (1)
Histone H3.3-K27M Neoantigen Vaccine Therapy (1)
ITI-3000 (1)
sipuleucel-T (1)
SNS-301 (1)
ERC1671 (1)
UCPVax (1)
VBI-1901 (1)
Versamune HPV (1)
PVS-RIPO (1)
GL-ONC1 (1)
RV001 (1)
SM-88 (1)
DNX-2401 (1)
DCP-001 (1)
ADCV01 (0)
ADP-TILIL7 (0)
ADU-623 (0)
ADXS-NEO (0)
AE 37 (0)
AIM-001 (0)
APVAC1 vaccine (0)
ATP150 (0)
ATP152 (0)
AV-MEL-1 (0)
AVX901 (0)
Ad-CCL21-DC (0)
AdHER2/neu DC Vaccine (0)
bioengineered allogeneic immune cells (0)
velimogene aliplasmid (0)
BB-MPI-03 (0)
BCG vaccine (0)
BI 1361849 (0)
BI 1821736 (0)
BI 1831169 (0)
BN-Brachyury (0)
BNT114 (0)
BNT115 (0)
BNT116 (0)
BSK-01 (0)
BVAC-B (0)
BVAC-C (0)
interferon alpha 2b (0)
dasiprotimut-T (0)
Bria-OTS (0)
CD25hi Treg depleted DLI (0)
CD40HVac (0)
CJRB-102 (0)
CMB305 (0)
CMD-602 (0)
CVGBM (0)
Escherichia coli (0)
celmoleukin (0)
recombinant human papillomavirus bivalent vaccine (0)
CodaLytic (0)
dendritic cell vaccine (0)
cancer vaccine MUC-1 (0)
DC-AdGMCAIX (0)
DCIKKb (0)
DCVAC/LuCa (0)
DCVAC/OvCa (0)
autologous dendritic cell vaccine leaded with autologous tumor cell lysate (0)
DI Leu16 IL-2 (0)
DNAJB1-PRKACA peptide vaccine (0)
Dendritic cell renal cell carcinoma fusion vaccine (0)
ELI-011 (0)
EO2401 (0)
ETBX-011 (0)
ETBX-021 (0)
ETBX-051 (0)
EVX-02 (0)
FHCT001 (0)
FR Alpha Peptide Vaccine (0)
FRAME-001 (0)
Fusion-VAC-XS15 (0)
GB104 (0)
GBM6-AD (0)
GC101 TIL (0)
GEN-009 (0)
GEN-011 (0)
GEN0101 (0)
GLSI-100 (0)
GNOS-PV01 (0)
GNOS-PV02 (0)
GP2 (0)
GRANITE (0)
GRN-1201 (0)
GSK2130579A (0)
GSK2302032A (0)
GT 316 (0)
GT201 (0)
GVAX leukemia vaccine (0)
GVAX lung cancer vaccine (0)
types 6, 11, 16, 18 (0)
human papillomavirus 9-valent vaccine, recombinant (0)
H1299 cell lysate with iscomatrix adjuvant vaccine (0)
H1299 lung cancer cell lysate vaccine with Montanide ISA-51 VG adjuvant (0)
HER-2 pulsed DC1 (0)
HER2- and HER3-primed dendritic cells (0)
HRXG-K-1939 (0)
HV-101 (0)
IMA970A (0)
ICT-107 (0)
ID-LV305 (0)
IDC-G305 (0)
IDH1R132H peptide vaccine (0)
IFx-2.0 (0)
IGV-001 (0)
IHV-001 (0)
IMA-901 (0)
IMA910 (0)
IMA950 (0)
IMF-001 (0)
IN01 (0)
INB-100 (0)
INO-3106 (0)
INO-5150 (0)
INVAC-1 (0)
IOV-001 (0)
IOV-4001 (0)
IP-001 (0)
IPM001 (0)
ITI-1001 (0)
IVAC_M_uID (0)
autologous γδ T lymphocytes (0)
MMP9FS (0)
KRAS peptide vaccine (0)
KSD-101 (0)
KSQ-004EX (0)
ATP128 (0)
LK101 (0)
LM103 (0)
LN-145 (0)
LN-145-S1 (0)
LYL845 (0)
22 (0)
axalimogene filolisbac (0)
DNP VACC (0)
MQ710 (0)
MT-101 (0)
MT-201 (0)
MV-NIS (0)
MVA-BN-Brachyury IV vaccine (0)
MVI-816 (0)
autologous dendritic cell vaccine (0)
Modi-1 (0)
NCI-4650 (0)
NDV HUJ (0)
NEO_PLIN2101 (0)
NOUS-209 (0)
NOUS-PEV (0)
NUMARZU-001 (0)
NY-ESO-1 Iscomatrix (0)
NY-ESO-1 combined with MPLA vaccine (0)
NEO-PV-01 (0)
OCV-501 (0)
ONCR-021 (0)
ONCR-788 (0)
ONT-10 (0)
OTSGC-A24 (0)
omidubicel (0)
ruxotemitide (0)
OriTIL-003 (0)
P30-EPS (0)
PANDA-VAC (0)
PDC*mel (0)
PEG IFN-a 2b (0)
PF-06753512 (0)
PF-07263689 (0)
PNV21 vaccine (0)
PRGN-2009 (0)
PV-001-DC (0)
PV-001-DV (0)
PVX2 (0)
Poly-ICLC matured DC adjuvanted NY-ESO-1/Melan-A-MART-1 peptide vaccine (0)
PolyPEPI 1018 (0)
rilimogene galvacirepvec (0)
RNA-NP vaccine (0)
ROSE12 (0)
RX-af01 (0)
HSP Gp96 vaccine (0)
S-588210 (0)
BCG vaccine (0)
SLATE-KRAS (0)
SQZ-PBMC-HPV (0)
STC-1010 (0)
SGN1 (0)
EMD 521873 (0)
HSV1716 (0)
tecemotide (0)
TG01 vaccine (0)
TG02 (0)
TG4050 (0)
THEO-310 (0)
TIDAL-01 (0)
TVGV-1 (0)
EGFREDVmiR-16 (0)
TetMYB (0)
PMCJ-9 (0)
live attenuated bacillus Calmette-Guerin (0)
Tri-Ad5 (0)
CMV-MVA vaccine (0)
UV1 (0)
Undisclosed VLP vaccine (0)
Undisclosed ovarian cancer vaccine (0)
V3-OVA (0)
V938 (0)
VAC2 (0)
VB10.16 (0)
VB10.NEO (0)
VPM1002 (0)
VSV-GP154 (0)
VTP-600 (0)
VTP-800 (0)
VV-GMCSF-Lact (0)
alpha-tocopheroloxyacetic acid (0)
Vx-006 (0)
WT2725 (0)
XH001 (0)
YE-NEO 001 (0)
Young TIL (0)
astuprotimut-R (0)
aDC1 vaccine (0)
ACA 125 (0)
allogeneic K562-GM tumor cell vaccine (0)
allogeneic Myeloma GM-CSF Vaccine (0)
alpha-lactalbumin vaccine (0)
PG2 (0)
autologous Tcm cellular immunotherapy (0)
autologous formalin-fixed tumor vaccine (0)
RG7813 (0)
ColoAd1 (0)
gp96-Ig vaccine (0)
iNeo-Vac-P01 (0)
iNeo-Vac-R01 (0)
mRNA-4157 (0)
mRNA-4359 (0)
mammaglobin-A DNA vaccine (0)
TG4010 (0)
STAT-401 (0)
multi-epitope melanoma peptide (0)
neoantigen DNA vaccine (0)
neoantigen peptide vaccine (0)
nonavalent HPV vaccine (0)
ADU-741 (0)
oral therapeutic vaccine V3-X (0)
p.DOM-WT1-126 DNA vaccine (0)
pING-hHER3FL (0)
polyvalent vaccine-KLH conjugate (0)
CDX-1401 (0)
CMN-001 (0)
self-amplifying RNA cancer vaccine (0)
TL-YCWP-DC (0)
UNO101 (0)
ITI-1000 (0)
INXN-1001 (0)
HS-410 (0)
RG6180 (4)
AV-GBM-1 (3)
SV-BR-1-GM (2)
tirvalimogene teraplasmid (2)
OSE 2101 (2)
lifileucel (1)
BNT111 (1)
EVX-01 (1)
Histone H3.3-K27M Neoantigen Vaccine Therapy (1)
ITI-3000 (1)
sipuleucel-T (1)
SNS-301 (1)
ERC1671 (1)
UCPVax (1)
VBI-1901 (1)
Versamune HPV (1)
PVS-RIPO (1)
GL-ONC1 (1)
RV001 (1)
SM-88 (1)
DNX-2401 (1)
DCP-001 (1)
ADCV01 (0)
ADP-TILIL7 (0)
ADU-623 (0)
ADXS-NEO (0)
AE 37 (0)
AIM-001 (0)
APVAC1 vaccine (0)
ATP150 (0)
ATP152 (0)
AV-MEL-1 (0)
AVX901 (0)
Ad-CCL21-DC (0)
AdHER2/neu DC Vaccine (0)
bioengineered allogeneic immune cells (0)
velimogene aliplasmid (0)
BB-MPI-03 (0)
BCG vaccine (0)
BI 1361849 (0)
BI 1821736 (0)
BI 1831169 (0)
BN-Brachyury (0)
BNT114 (0)
BNT115 (0)
BNT116 (0)
BSK-01 (0)
BVAC-B (0)
BVAC-C (0)
interferon alpha 2b (0)
dasiprotimut-T (0)
Bria-OTS (0)
CD25hi Treg depleted DLI (0)
CD40HVac (0)
CJRB-102 (0)
CMB305 (0)
CMD-602 (0)
CVGBM (0)
Escherichia coli (0)
celmoleukin (0)
recombinant human papillomavirus bivalent vaccine (0)
CodaLytic (0)
dendritic cell vaccine (0)
cancer vaccine MUC-1 (0)
DC-AdGMCAIX (0)
DCIKKb (0)
DCVAC/LuCa (0)
DCVAC/OvCa (0)
autologous dendritic cell vaccine leaded with autologous tumor cell lysate (0)
DI Leu16 IL-2 (0)
DNAJB1-PRKACA peptide vaccine (0)
Dendritic cell renal cell carcinoma fusion vaccine (0)
ELI-011 (0)
EO2401 (0)
ETBX-011 (0)
ETBX-021 (0)
ETBX-051 (0)
EVX-02 (0)
FHCT001 (0)
FR Alpha Peptide Vaccine (0)
FRAME-001 (0)
Fusion-VAC-XS15 (0)
GB104 (0)
GBM6-AD (0)
GC101 TIL (0)
GEN-009 (0)
GEN-011 (0)
GEN0101 (0)
GLSI-100 (0)
GNOS-PV01 (0)
GNOS-PV02 (0)
GP2 (0)
GRANITE (0)
GRN-1201 (0)
GSK2130579A (0)
GSK2302032A (0)
GT 316 (0)
GT201 (0)
GVAX leukemia vaccine (0)
GVAX lung cancer vaccine (0)
types 6, 11, 16, 18 (0)
human papillomavirus 9-valent vaccine, recombinant (0)
H1299 cell lysate with iscomatrix adjuvant vaccine (0)
H1299 lung cancer cell lysate vaccine with Montanide ISA-51 VG adjuvant (0)
HER-2 pulsed DC1 (0)
HER2- and HER3-primed dendritic cells (0)
HRXG-K-1939 (0)
HV-101 (0)
IMA970A (0)
ICT-107 (0)
ID-LV305 (0)
IDC-G305 (0)
IDH1R132H peptide vaccine (0)
IFx-2.0 (0)
IGV-001 (0)
IHV-001 (0)
IMA-901 (0)
IMA910 (0)
IMA950 (0)
IMF-001 (0)
IN01 (0)
INB-100 (0)
INO-3106 (0)
INO-5150 (0)
INVAC-1 (0)
IOV-001 (0)
IOV-4001 (0)
IP-001 (0)
IPM001 (0)
ITI-1001 (0)
IVAC_M_uID (0)
autologous γδ T lymphocytes (0)
MMP9FS (0)
KRAS peptide vaccine (0)
KSD-101 (0)
KSQ-004EX (0)
ATP128 (0)
LK101 (0)
LM103 (0)
LN-145 (0)
LN-145-S1 (0)
LYL845 (0)
22 (0)
axalimogene filolisbac (0)
DNP VACC (0)
MQ710 (0)
MT-101 (0)
MT-201 (0)
MV-NIS (0)
MVA-BN-Brachyury IV vaccine (0)
MVI-816 (0)
autologous dendritic cell vaccine (0)
Modi-1 (0)
NCI-4650 (0)
NDV HUJ (0)
NEO_PLIN2101 (0)
NOUS-209 (0)
NOUS-PEV (0)
NUMARZU-001 (0)
NY-ESO-1 Iscomatrix (0)
NY-ESO-1 combined with MPLA vaccine (0)
NEO-PV-01 (0)
OCV-501 (0)
ONCR-021 (0)
ONCR-788 (0)
ONT-10 (0)
OTSGC-A24 (0)
omidubicel (0)
ruxotemitide (0)
OriTIL-003 (0)
P30-EPS (0)
PANDA-VAC (0)
PDC*mel (0)
PEG IFN-a 2b (0)
PF-06753512 (0)
PF-07263689 (0)
PNV21 vaccine (0)
PRGN-2009 (0)
PV-001-DC (0)
PV-001-DV (0)
PVX2 (0)
Poly-ICLC matured DC adjuvanted NY-ESO-1/Melan-A-MART-1 peptide vaccine (0)
PolyPEPI 1018 (0)
rilimogene galvacirepvec (0)
RNA-NP vaccine (0)
ROSE12 (0)
RX-af01 (0)
HSP Gp96 vaccine (0)
S-588210 (0)
BCG vaccine (0)
SLATE-KRAS (0)
SQZ-PBMC-HPV (0)
STC-1010 (0)
SGN1 (0)
EMD 521873 (0)
HSV1716 (0)
tecemotide (0)
TG01 vaccine (0)
TG02 (0)
TG4050 (0)
THEO-310 (0)
TIDAL-01 (0)
TVGV-1 (0)
EGFREDVmiR-16 (0)
TetMYB (0)
PMCJ-9 (0)
live attenuated bacillus Calmette-Guerin (0)
Tri-Ad5 (0)
CMV-MVA vaccine (0)
UV1 (0)
Undisclosed VLP vaccine (0)
Undisclosed ovarian cancer vaccine (0)
V3-OVA (0)
V938 (0)
VAC2 (0)
VB10.16 (0)
VB10.NEO (0)
VPM1002 (0)
VSV-GP154 (0)
VTP-600 (0)
VTP-800 (0)
VV-GMCSF-Lact (0)
alpha-tocopheroloxyacetic acid (0)
Vx-006 (0)
WT2725 (0)
XH001 (0)
YE-NEO 001 (0)
Young TIL (0)
astuprotimut-R (0)
aDC1 vaccine (0)
ACA 125 (0)
allogeneic K562-GM tumor cell vaccine (0)
allogeneic Myeloma GM-CSF Vaccine (0)
alpha-lactalbumin vaccine (0)
PG2 (0)
autologous Tcm cellular immunotherapy (0)
autologous formalin-fixed tumor vaccine (0)
RG7813 (0)
ColoAd1 (0)
gp96-Ig vaccine (0)
iNeo-Vac-P01 (0)
iNeo-Vac-R01 (0)
mRNA-4157 (0)
mRNA-4359 (0)
mammaglobin-A DNA vaccine (0)
TG4010 (0)
STAT-401 (0)
multi-epitope melanoma peptide (0)
neoantigen DNA vaccine (0)
neoantigen peptide vaccine (0)
nonavalent HPV vaccine (0)
ADU-741 (0)
oral therapeutic vaccine V3-X (0)
p.DOM-WT1-126 DNA vaccine (0)
pING-hHER3FL (0)
polyvalent vaccine-KLH conjugate (0)
CDX-1401 (0)
CMN-001 (0)
self-amplifying RNA cancer vaccine (0)
TL-YCWP-DC (0)
UNO101 (0)
ITI-1000 (0)
INXN-1001 (0)
HS-410 (0)
›
Associations
News
Trials
Filter by
Latest
4ms
TVI-AST-008: Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM) (clinicaltrials.gov)
P2/3, N=120, Recruiting, TVAX Biomedical | Trial completion date: Mar 2026 --> Mar 2027 | Trial primary completion date: Dec 2025 --> Dec 2026
4 months ago
Trial completion date • Trial primary completion date
|
MGMT (6-O-methylguanine-DNA methyltransferase)
|
temozolomide • TVI-Brain-1
11ms
Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM) (clinicaltrials.gov)
P2/3, N=96, Recruiting, TVAX Biomedical
11 months ago
Trial completion date • Trial primary completion date
|
MGMT (6-O-methylguanine-DNA methyltransferase)
|
temozolomide • TVI-Brain-1
1year
Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM) (clinicaltrials.gov)
P2/3, N=96, Recruiting, TVAX Biomedical | Phase classification: P2b --> P2/3
1 year ago
Phase classification
|
MGMT (6-O-methylguanine-DNA methyltransferase)
|
temozolomide • TVI-Brain-1
1year
Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM) (clinicaltrials.gov)
P2b, N=96, Recruiting, TVAX Biomedical | Not yet recruiting --> Recruiting
1 year ago
Enrollment open
|
MGMT (6-O-methylguanine-DNA methyltransferase)
|
temozolomide • TVI-Brain-1
over1year
Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM) (clinicaltrials.gov)
P2b, N=96, Not yet recruiting, TVAX Biomedical | Initiation date: Jun 2023 --> Sep 2023
over 1 year ago
Trial initiation date
|
MGMT (6-O-methylguanine-DNA methyltransferase)
|
temozolomide • TVI-Brain-1
over1year
TVI-Brain-1 in Expanded Access Patient (clinicaltrials.gov)
P=N/A, Available, TVAX Biomedical
over 1 year ago
New trial
|
TVI-Brain-1
over1year
Study To Test the Safety and Efficacy of TVI-Brain-1 As A Treatment for Recurrent Grade IV Glioma (clinicaltrials.gov)
P2, N=14, Completed, TVAX Biomedical | N=86 --> 14
over 1 year ago
Enrollment change
|
TVI-Brain-1
over1year
Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed o6-methylguanine-DNA-methyltransferase (MGMT) Negative Glioblastoma Multiforme (GBM) (clinicaltrials.gov)
P2b, N=96, Not yet recruiting, TVAX Biomedical | Initiation date: Mar 2023 --> Jun 2023
over 1 year ago
Trial initiation date
|
MGMT (6-O-methylguanine-DNA methyltransferase)
|
temozolomide • TVI-Brain-1
almost2years
Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed o6-methylguanine-DNA-methyltransferase (MGMT) Negative Glioblastoma Multiforme (GBM) (clinicaltrials.gov)
P2b, N=96, Not yet recruiting, TVAX Biomedical
almost 2 years ago
New P2b trial
|
MGMT (6-O-methylguanine-DNA methyltransferase)
|
temozolomide • TVI-Brain-1
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login